INMED PHARMACEUTICALS INC.: revenue
Revenue for INMED PHARMACEUTICALS INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All INMED PHARMACEUTICALS INC. financial histories
What this measure means
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
Exact concept: us-gaap:Revenues. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2021-07-01 to 2025-06-30. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2024-07-01 | 2025-06-30 | 4,942,633 | USD | 2025-09-23 | 10-K · 0001213900-25-090210 |
| 2023-07-01 | 2024-06-30 | 4,597,730 | USD | 2025-09-23 | 10-K · 0001213900-25-090210 |
| 2022-07-01 | 2023-06-30 | 4,135,561 | USD | 2024-09-30 | 10-K · 0001213900-24-082843 |
| 2021-07-01 | 2022-06-30 | 1,089,435 | USD | 2023-09-29 | 10-K · 0001213900-23-080842 |
Related financial histories
- INMED PHARMACEUTICALS INC.: total assets
- INMED PHARMACEUTICALS INC.: total liabilities
- INMED PHARMACEUTICALS INC.: stockholders equity
- INMED PHARMACEUTICALS INC.: cash and cash equivalents
- INMED PHARMACEUTICALS INC.: net income or loss
- INMED PHARMACEUTICALS INC.: operating cash flow
- INMED PHARMACEUTICALS INC.: capital expenditure payments
- INMED PHARMACEUTICALS INC.: financing cash flow
- INMED PHARMACEUTICALS INC.: investing cash flow
- INMED PHARMACEUTICALS INC.: retained earnings or deficit
- INMED PHARMACEUTICALS INC.: basic weighted-average shares
- INMED PHARMACEUTICALS INC.: diluted weighted-average shares
- INMED PHARMACEUTICALS INC.: basic earnings per share
- INMED PHARMACEUTICALS INC.: diluted earnings per share
- INMED PHARMACEUTICALS INC.: net property, plant and equipment
- INMED PHARMACEUTICALS INC.: share-based compensation expense
- INMED PHARMACEUTICALS INC.: operating income or loss
- INMED PHARMACEUTICALS INC.: current assets
- INMED PHARMACEUTICALS INC.: current liabilities
- INMED PHARMACEUTICALS INC.: net finite-lived intangible assets
- INMED PHARMACEUTICALS INC.: net current accounts receivable
- INMED PHARMACEUTICALS INC.: operating expenses
- INMED PHARMACEUTICALS INC.: net inventory
- INMED PHARMACEUTICALS INC.: gross profit
- INMED PHARMACEUTICALS INC.: cost of revenue
- INMED PHARMACEUTICALS INC.: research and development expense
Inspect the source
- Entity
- INMED PHARMACEUTICALS INC. / CIK 0001728328
- Captured
- 2026-09-21T17:27:41.396Z
- SEC response SHA-256
1f73e76cc8d3847e3658f72033c4ed33ce1de4528067a6f82d159b8aa5c1b91f
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001728328.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))